CYH33 + olaparib

CYH33 + olaparib is an oral combination investigational therapy comprised of a highly selective phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor (CYH33) and a poly(ADP-ribose) polymerase (PARP) inhibitor (olaparib). CYH33 inhibits PI3Kα, downregulating BRCA1/2 protein expression, thereby increasing homologous recombination repair (HRR) deficiency. Olaparib inhibits PARP enzymes (primarily PARP1 and PARP2), leading to the accumulation of DNA damage, synthetic lethality, and cancer cell death, particularly in tumors with DNA damage repair (DDR) or BRCA mutations. The combination aims to overcome PARP inhibitor resistance and optimize anti-tumor activity, and is under clinical study for advanced solid tumors (e.g., recurrent high-grade serous ovarian, fallopian tube, or primary peritoneal cancer) characterized by DDR or PIK3CA mutations. The regimen is administered orally, based on investigational clinical protocols[1][3][5].

Brand names

Lynparza

Other names

CYH33 + olaparib